| [1] |
Zardavas D, Irrthum A, Swanton C, et al. Clinical management of breast cancer heterogeneity[J]. Nat Rev Clin Oncol, 2015, 12(7): 381-394.
|
| [2] |
Lakhani SR, Ellis IO, Schnitt SJ, et al. World Health Organization classification of tumours of the breast[M]. Lyon: IARC Press, 2012.
|
| [3] |
Perou CM, Srlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406(6797): 747-752.
|
| [4] |
Srlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J]. Proc Natl Acad Sci U S A, 2001, 98(19): 10 869-10 874.
|
| [5] |
Anderson WF, Rosenberg PS, Prat A, et al. How many etiological subtypes of breast cancer: two, three, four, or more？[J]. J Natl Cancer Inst, 2014, 106(8): dju165.
|
| [6] |
朱坤兵，徐灿，李晓霞，等. 乳腺癌分子分型与新辅助化疗效果的关系[J/CD]. 中华乳腺病杂志(电子版), 2016，10(3)：166-169.
|
| [7] |
Vera-Badillo FE, Templeton AJ, de Gouveia P, et al. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis[J]. J Natl Cancer Inst, 2014, 106(1): djt319.
|
| [8] |
Dvorkin-Gheva A, Hassell JA. Identification of a novel luminal molecular subtype of breast cancer[J]. PLoS One, 2014, 9(7): e103514.
|
| [9] |
Maisonneuve P, Disalvatore D, Rotmensz N, et al. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes[J]. Breast Cancer Res, 2014, 16(3): R65.
|
| [10] |
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 [J]. Ann Oncol, 2013, 24(9): 2206-2223.
|
| [11] |
Rakha EA, Soria D, Green AR, et al. Nottingham Prognostic Index Plus (NPI＋): a modern clinical decision making tool in breast cancer[J]. Br J Cancer, 2014, 110(7): 1688-1697.
|
| [12] |
Qi JP, Yang YL, Zhu H, et al. Expression of the androgen receptor and its correlation with molecular subtypes in 980 Chinese breast cancer patients [J]. Breast Cancer (Auckl), 2012, 6(1): 1-8.
|
| [13] |
Zhang Z, Wang J, Tacha DE, et al. Folate receptor α associated with triple-negative breast cancer and poor prognosis [J]. Arch Pathol Lab Med, 2014, 138(7): 890-895.
|
| [14] |
Hammond ME, Hayes DF, Dowestt M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version) [J]. Arch Pathol Lab Med, 2010, 134(7): e48-e72.
|
| [15] |
Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update [J]. J Clin Oncol, 2013, 31(31): 3997-4013.
|
| [16] |
Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group [J]. J Natl Cancer Inst, 2011, 103(22): 1656-1664.
|
| [17] |
Polley MY, Leung SC, Gao D, et al. An international study to increase concordance in Ki67 scoring[J]. Mod Pathol, 2015, 28(6): 778-786.
|
| [18] |
De Azarmbuja E, Cardosi F, de Castro G, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12, 155 patients[J]. Br J Cancer, 2007, 96(10): 1504-1513.
|
| [19] |
Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtyped of dealing with the diversity of breast cancer-highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011[J]. Ann Oncol, 2011, 22(8): 1736-1747.
|
| [20] |
Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 [J]. Ann Oncol, 2015, 26(8): 1533-1546.
|
| [21] |
Curigliano G, Burstein HJ, Winer E, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017[J]. Ann Oncol, 2017, 28(8): 1700-1712.
|
| [22] |
Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J]. Clin Cancer Res, 2004, 10(16): 5367-5374.
|
| [23] |
邓淼，刘江波，刘起鹏，等. CK5/6和Ki67表达与乳腺癌分子病理特征关系的临床分析[J/CD]. 中华乳腺病杂志(电子版), 2015，9(6)：380-386.
|
| [24] |
Overgaard J, Yilmaz M, Gulberg P, et al. TP53 is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer[J]. Acta Oncol, 2000, 39(9): 327-333.
|
| [25] |
Rozan S, Vincent-Salomon A, Zafrani B, et al. No significant predictive value of C-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer[J]. Int J Cancer, 1998, 79(1): 27-33.
|
| [26] |
Gatza ML, Silva GO, Parker JS, et al. An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer[J]. Nat Genet, 2014, 46(10): 1051-1059.
|
| [27] |
Hallett RM, Hassell JA. Estrogen independent gene expression defines clinically relevant subgroups of estrogen receptor positive breast cancer[J]. BMC Cancer, 2014, 14: 871.
|
| [28] |
Jiang YZ, Yu KD, Zuo WJ, et al. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival[J]. Cancer, 2014, 120(9): 1329-1337.
|
| [29] |
Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer[J]. J Natl Cancer Inst, 2009, 101(10): 736-750.
|
| [30] |
Prat A, Cheang MC, Martin M, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer[J]. J Clin Oncol, 2013, 31(2): 203-209.
|
| [31] |
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors[J]. Nature, 2012, 490(7418): 61-70.
|
| [32] |
Ades F, Zardavas D, Bozovic-Spasojevic I, et al. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives[J]. J Clin Oncol, 2014, 32(25): 2794-2803.
|
| [33] |
Cancello G, Maisonneuve P, Rotmansz N, et al. Progesterone receptor loss identifies luminal B breast cancer subgroups at higher risk of relapse[J]. Ann Oncol, 2013, 24(3): 661-668.
|
| [34] |
Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with Genomic Health recurrence score in early breast cancer[J]. J Clin Oncol, 2011, 29(32): 4273-4278.
|
| [35] |
Klein ME, Dabbs DJ, Shuai Y, et al. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis[J]. Mod Pathol, 2013, 26(5): 658-664.
|
| [36] |
Zong Y, Zhu L, Wu J, et al. Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study[J]. PLoS One, 2014, 9(8): e95629.
|
| [37] |
Green AR, Barros FF, Abdel-Fatah TM, et al. HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2＋ breast cancer[J]. Breast Cancer Res Treat, 2014, 145(1): 33-44.
|
| [38] |
Fountzilas G, Dafni U, Bobos M, et al. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel[J]. PLoS One, 2012, 7(6): e34946.
|
| [39] |
Wu VS, Kanaya N, Lo C, et al. From bench to bedside: what do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer[J]. J Steroid Biochem Mol Biol, 2015, 153: 45-53.
|
| [40] |
Kneubil MC, Brollo J, Botteri E, et al. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction[J]. Eur J Surg Oncol, 2013, 39(3): 260-265.
|
| [41] |
Alqaisi A, Chen L, Romond E, et al. Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research[J]. Breast Cancer Res Treat, 2014, 148(2): 437-444.
|
| [42] |
Parise CA, Caggiano C. Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers[J]. J Cancer Epidermiol, 2014, 2014: 469 251.
|
| [43] |
Staaf J, Ringner M, Vallon-CHristersson J, et al. Identification of subtypes in human epidermal growth factor receptor 2-positive breast cancer reveals a gene signature prognostic of outcome[J]. J Clin Oncol, 2010, 28(11): 1813-1820.
|
| [44] |
Badve S, Dabbs DJ, Schnitt SJ, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologist and oncologists[J]. Mod Pathol, 2011, 24(2): 157-167.
|
| [45] |
Geyer FC, Pareja F, Weigelt B, et al. The spectrum of triple-negative breast disease: high- and low-grade lesions[J]. Am J Pathol, 2017, 187(10): 2139-2151.
|
| [46] |
Lehmann BD, Bauer JA, Chen X, et al. Identification of human triplenegative breast cancer subtypes and preclinical models for selection of targeted therapies[J]. J Clin Invest, 2011, 121(7): 2750-2767.
|
| [47] |
Masuda H, Baggerly KA, Wang Y, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes[J]. Clin Cancer Res, 2013, 19(19): 5533-5540.
|
| [48] |
Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes[J]. Clin Cancer Res, 2009, 15(7): 2302-2310.
|
| [49] |
Lehmann-Che J, Harny AS, Porcher R, et al. Molecular apocrine breast cancer are aggressive estrogen receptor negative tumors over-expression either HER2 or GCDFP15[J]. Breast Cancer Res, 2013, 15(3): R37.
|
| [50] |
Lu S, Singh K, Mangray S, et al. Claudin expression in high grade invasive ductal carcinoma of the breast: correlation with the molecular subtype[J]. Mod Pathol, 2013, 26(4): 485-495.
|
| [51] |
Sabatier R, Finetti P, Guille A, et al. Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization[J]. Mol Cancer, 2014, 13: 228.
|
| [52] |
Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes[J]. J Clin Oncol, 2009, 27(8): 1160-1167.
|
| [53] |
Weigelt B, Mackay A, A'hern R, et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis[J]. Lancet Oncol, 2010, 11(4): 339-349.
|
| [54] |
Cheang MC, Martin M, Nielsen TO, et al. Defining breast cancer intrinsic subtypes by quantitative receptor expression[J]. Oncologist, 2015, 20(5): 474-482.
|
| [55] |
Prat A, Carey L, Adamo B, et al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer[J]. J Natl Cancer Inst, 2014, 106(8). pii: dju152.
|
| [56] |
Zhang Z, Wang J, Skinner KA, et al. Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression [J]. Histopathology, 2014, 65(4): 508-516.
|
| [57] |
Knox AJ, Scaling AL, Pinto MP, et al. Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease[J]. Breast Cancer Res, 2014, 16(4): 418-430.
|